Stem cell trial success could lead to new heart disease therapies

Stem cell trial success could lead to new heart disease therapies

The key objective of the EU-funded CARE-MI project, which was completed in September 2015, was to evaluate the safety and efficacy of AlloCSC-01, a suspension of allogeneic human cardiac stem cells (CSCs) in patients who have suffered a heart attack. This serious condition occurs when blood stops flowing to a part of the heart, causing damage to the heart muscle.

In this way, the CARE-MI project has developed a new approach to limit based on the activation of the 's natural repair mechanisms in response to damage. The success of the project trials will enable the researchers to perform further analyses on stem cell treatments, with final results expected in the first half of 2017.

The hope is that AlloCSC-01 could become a revolutionary new approach to preventing and the onset of (CHF) after a , boosting patient care and leading to a new market in . In the US and Europe alone, around 1.5 million heart attacks are treated annually.

Initial recovery after a heart attack is often followed by chronic . This is partly because current therapies, while initially successful, are unable to regenerate damaged tissue. As chronic heart failure is responsible for an annual mortality rate of 18 %, the project team saw a clear need to find treatments capable of tissue regeneration.

Various cell therapies have already been proposed and tested but have proven to be marginally effective. Furthermore, the cost and the complexity of these clinical procedures make these therapies unsuitable for treating the large number of patients that need affordable and readily available products.

The CARE-MI team therefore wanted to drastically improve on these current heart disease treatments. A total of eight clinical centres of reference in cardiology participated in project trials, led by Prof. Fernández-Avilés of Hospital Gregorio Marañón in Madrid, Spain, and Prof. Stefan Janssens of KU Leuven, Belgium.

The project team built on recent research that found that heart muscles contain pluripotent cells. These cells act like endogenous cardiac (eCSCs), which are capable of anatomical and functional regeneration. The project then focused on the clinical development and testing of therapies to activate eCSCs. The ultimate objective has been to make these products biocompatible, affordable, readily available and compliant with regulatory standards.

Significant inroads have been made by the CARE-MI consortium with regard to good manufacturing practice, accredited product development and testing. Allogeneic cell batches (i.e. from different human donors) were used for pre-clinical and stability tests and results confirmed their robustness and bio-equivalency.

Furthermore, extensive testing also confirmed their anti-inflammatory and hypo-immunogenic properties as well as their capacity to promote healing. Safety and bio-distribution tests were also shown to be highly promising with no major adverse effects. The team also succeeded in optimising dosing, timing and delivery methods.

A new cell production platform is now being constructed, which will enable researchers to move onto a more advanced clinical stage and ultimately bring these therapies to market.


Explore further

New research reveals combined cell therapy enhances cardiac performance following heart attack

More information: For further information please visit the CARE-MI project website: www.caremiproject.eu/
Provided by CORDIS
Citation: Stem cell trial success could lead to new heart disease therapies (2015, November 25) retrieved 24 March 2019 from https://medicalxpress.com/news/2015-11-stem-cell-trial-success-heart.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
12 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more